Competition weekly news summary
12 October 2012

Conferences and Speeches

  • Reviewing the Commission's Regional aid guidelines
    Open Days – 10th European week of regions and cities - High level seminar on Competition, State aid and regional development, Brussels, Joaquín Almunia
    11 October 2012
    "We have seen examples in Ireland, where the pharmaceutical industry made large investments, and in Poland and other countries that joined the EU after 2004 with similar ventures by household electronics giants. However, many other elements can better explain investment strategies; for instance, a skilled workforce, the level of taxation, the quality of infrastructures, and a pro-business regulatory environment. This is why we need to ensure that subsidies go only where they can tip the balance and trigger new investment and job creation."
    Read full speech >
  • Presenting the Competition Policy Work Programme for 2013/14
    ECON, European Parliament, Brussels, Joaquín Almunia
    8 October 2012
    "Some of you may have noticed that in my recent speeches I've been insisting on the need to establish a stronger link between the different competition policy instruments and our main priorities in this difficult juncture: setting the best conditions to stimulate growth and deepening and extending the Single Market as one of our best tools to do it. The initiatives I am presenting to you today are inspired by these considerations. I intend to improve an already excellent system so that competition policy can respond to Europe's current challenges at its best."
    Read full speech >


  • Commission approves acquisition of US-based distributor Brightpoint by US rival Ingram Micro
    12 October 2012
    The Commission has cleared the proposed acquisition of the US-based distributor of mobility/telecommunications products Brightpoint by Ingram Micro of the US, a distributor of electronic products. The Commission concluded that the concentration would not raise competition concerns, because the merged entity will continue to face sufficient competitive constraints, including on narrow market segments.
    Read more >
  • Commission approves acquisition of pharma company Actavis by rival Watson
    5 October 2012
    The Commission has cleared the proposed acquisition of the Swiss-based pharmaceutical company Actavis by the generic pharmaceutical company Watson of the US. The Commission concluded that the merged entity would continue to face a number of strong competitors.
    Read more >


Editorial and legal information

Published by the Competition Directorate General of the European Commission. The content of this publication does not necessarily reflect the official position of the European Commission. Neither the Commission nor any person acting on its behalf is responsible for the use which might be made of the above information.

© European Union, 2012. Reproduction is authorised provided the source is acknowledged.

Competition website